A multicentre, randomized, open-label, single dose, two-treatment, three-period, three sequence, partial replicate, crossover, pivotal bioequivalence study of Test capecitabine 500 mg tablets manufactured by Reliance Life Sciences Pvt. Ltd., India with Xeloda (capecitabine 500 mg) manufactured by Roche Pharma AG, Germany in adult, human, cancer patients under fed condition

Trial Profile

A multicentre, randomized, open-label, single dose, two-treatment, three-period, three sequence, partial replicate, crossover, pivotal bioequivalence study of Test capecitabine 500 mg tablets manufactured by Reliance Life Sciences Pvt. Ltd., India with Xeloda (capecitabine 500 mg) manufactured by Roche Pharma AG, Germany in adult, human, cancer patients under fed condition

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer; Colorectal cancer
  • Focus Pharmacokinetics
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 24 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top